E Arch Therapeutics Is A Life Sciences Company To Put On Your Radar: CEO Terrance Norch

TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Today I am discussing an emerging life sciences company called Arch Therapeutics (ARTH). This company operates within the life sciences sector, has roughly an $18 million market cap and is listed on the OTC QB. One of the reasons why this company is an interesting investment opportunity is that it is targeting a large, underserved indication in Stasis and Barrier applications. Specifically, Arch is targeting the rapid cessation of bleeding and control of fluid leakage during surgery and trauma care. This represents a multi-billion dollar opportunity for Arch, and is only expected to increase as the market grows through 2017.

While major medical device developers are invested in Stasis and Barrier products, there are very few companies that offer real exposure to the market. According to my research, Arch is one such opportunity that is completely immersed in the development of medical devices targeting this underserved indication. Thus, should the company advance a product to market (which is expected as early as 2016), investors could be provided an opportunity for growth that is not possible in some of the more prominent medical device companies. It is important to note, however, that investing in such a company comes with the inherent risks of shareholder dilution, clinical failure, and intense market competition. Thus, it is at the discretion of you, the reader, to approach Arch given the significant risks that accompany any investment in the equity.

Given the lack of coverage of Arch, I felt compelled to further investigate the company's various clinical developments. Accordingly, I reached out for an interview with Dr. Terrance Norch, President, CEO and Director of Arch. Please read CEO Norch's bio on the company website, available here. Following is my interview with Dr. Norch.

Could you summarize ARTH's pipeline?

Our pipeline stems from the self-assembling technology for which we have a worldwide exclusive license from MIT. We have broadly described our interest in the field I describe as Stasis and Barrier Applications. That field covers a range of applications that interest us from surgery to trauma to other areas we have not yet disclosed. We are first focused on bleeding in surgical procedures, whether plastic surgery or internal surgical procedures. But stopping bleeding in trauma is close behind in our pipeline. We have also announced a product that should address a number of needs for hard to heal ulcers. These include diabetic foot ulcers, which can ooze, bleed, and be generally hard to protect during the healing process. At the end of the day, if there is a hole in the body, we believe that the Arch Therapeutics technology may help solve the myriad problems encountered, and our pipeline will be focused accordingly. While details are not being disclosed for competitive reasons, the number of products we wish to develop can be counted in double digits.

1 2 3 4
View single page >> |

Disclosure: The information presented is for entertainment purposes only, and in no way should it be construed as investment advice. I am not receiving any compensation for the said article ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.